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3) Bone loss with increasing age may be due to decreased bone formation and increased bone resorption. Pharmacologic and nutritional factors may prevent bone loss with aging. 4, 5) Chemical compounds in food that act on bone metabolism, however, are poorly understood.
Micronutrients and phytochemicals found in vegetables and fruit, such as carotenoids, are potential chemoprevenetive agents. Carotenoids have been shown to play a possible biological role in cancer prevention. 6) This preventive effect on osteoporosis, however, has not been fully clarified. Vitamin A is known to have a detrimental effect on bone at high doses. High levels of vitamin A lead to accelerated bone resorption, bone fractures, and osteoporotic bone lesions in animals. [7] [8] [9] b-Cryptoxanthin is a carotenoid abundant in Satsuma mandarin (Citrus unshiu MARC.), and it is enzymatically converted from b-carotene (provitamin A) in plants. Of the various carotenoids (including b-cryptoxanthin, lutein, lycopene, and b-carotene) and rutin (quercetin-3-rutinoside), b-cryptoxanthin has been found to have a unique anabolic effect on bone calcification in vitro. 10) b-Cryptoxanthin has a stimulatory effect on bone formation and an inhibitory effect on bone resorption in rat femoral tissue culture in vitro.
11) bCryptoxanthin can stimulate cell proliferation and mineralization in osteoblastic cells in vitro, 12, 13) and it can inhibit osteoclast-like cell formation induced by bone-resorbing factors in mouse marrow cultures in vitro. 14) Thus b-cryptoxanthin has been demonstrated to have a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption in vitro.
Oral administration of b-cryptoxanthin has been shown to have an anabolic effect on bone components in young and aged rats in vivo. 15, 16) This study was undertaken to determine whether b-cryptoxanthin has a preventive effect on bone loss in the pathophysiologic state. We found that oral administration of the agent induces this effect on femoral tissues in streptozotocin (STZ)-diabetic rats in vivo.
MATERIALS AND METHODS
Chemicals STZ was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). b-Cryptoxanthin was obtained from Extrasynthese (Lyon-Nord, France). Other chemicals were of reagent grade from Wako Pure Chemical Industries (Osaka, Japan).
Animals Male Wistar rats (conventional) weighing 90-95 g (4 weeks old) were obtained from Japan SLC (Hamamatsu, Japan). The animals were fed commercial laboratory chow (solid) containing 1.1% calcium and 1.1% phosphorus at room temperature of 25°C, with free access to distilled water.
Administration Procedures STZ was dissolved in sodium citrate 50 mM (pH 4.5) solution containing NaCl 150 mM.
17) The solution (6.0 mg/0.5 ml/100 g body weight) was subcutaneously administered to rats, and 7 or 14 d later the animals were killed by exsanguination. In another experiment, b-cryptoxanthin was dissolved in corn oil at a concentration of 10 or 20 mg/ml and then 5 or 10 mg/0.5 ml/100 g body weight was orally administered to rats through a stomach tube once daily for 7 or 14 d. Control rats received corn oil (0.5 ml/100 g body weight) orally. b-Cryptoxanthin was orally administered 3 h after the administration of STZ (6.0 mg/100 g). The animals were killed 24 h after the last administration by cardiac puncture under light ether anesthesia, and the blood and femur were removed immediately.
Analytical Procedures Blood samples obtained by cardiac puncture were centrifuged 30 min after collection, and the serum was separated. Serum was frozen at Ϫ80°C until assay. Serum glucose, triglyceride, calcium, and inorganic phosphorus concentrations were determined using an assay Kit (Wako Pure Chemical Industries).
The diaphyseal or metaphyseal tissues were dried for 16 h at 110°C. Calcium was determined using atomic absorption specrophotometry. 18) Calcium content in bone tissues was expressed as milligrams per gram of dry bone.
To assay alkaline phosphatase activity, the diaphyseal or metaphyseal tissues were immersed in 3.0 ml of ice-cold barbital buffer 6.6 mM (pH 7.4), cut into small pieces, and disrupted for 60 s with an ultrasonic device. The supernatant centrifuged at 600ϫg for 5 min was used to measure enzyme activity. The enzyme assay was carried out under optimal conditions. Alkaline phosphatase activity was determined using the method of Walter and Schutt. 19) Enzyme activity was expressed as micromole of p-nitrophenol liberated per minute per milligram of protein. The protein concentration was determined using the method of Lowry et al. 20) To measure bone DNA content, the diaphyseal or metaphyseal tissues were shaken with 4.0 ml of ice-cold 0.1 N NaOH solution for 24 h after the homogenization of the bone tissues. 21) After alkaline extraction, the samples were centrifuged at 1000ϫg for 5 min, and the supernatant was determined using the method of Ceriotti 22) and expressed as the amount of DNA (mg) per g wet weight of bone tissue.
Statistical Analysis The significance of differences between values was estimated using Student's t-test. We also used multiple ANOVA to compare the treatment groups. A p value of less 0.05 was considered to indicate a statistically significant difference.
RESULTS

Effects of b b-Cryptoxanthin Administration on Serum Components in STZ-Diabetic Rats
Rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and the animals were orally administered b-cryptoxanthin (5 or 10 mg/100 g body weight) once daily for 7 or 14 d. The body weight of animals was significantly decreased 7 or 14 d after the administration of STZ. This reduction was significantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g) for 14 d (Table 1) .
Serum glucose and triglyceride levels were markedly elevated in rats administered STZ, indicating that the administration induces a diabetic state. These increases were significantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g) for 14 d (Table 1 ). The administration of bcryptoxanthin (5 or 10 mg/100 g) for 14 d did not have any effect on serum glucose and triglyceride levels in normal rats (data not shown).
The serum calcium levels were significantly elevated 14 d after the the administration of STZ (Table 2 ). This increase was significantly prevented by administration of b-cryptoxanthin (5 or 10 mg/100 g) for 14 d. Serum inorganic phosphorus levels were significantly decreased 7 or 14 d after STZ administration (Table 2 ). This decrease was significantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g) for 7 or 14 d. The administration of b-cryptoxanthin (5 or 10 mg/100 g) to normal rats for 7 or 14 d had no effect on serum calcium and inorganic phosphorus levels (data not shown).
Effects of b b-Cryptoxanthin Administration on Bone Components in STZ-Diabetic Rats
The effects of b-cryptoxanthin administration on bone components in the femoraldiaphyseal and -metaphyseal tissues of STZ-diabetic rats was examined. Calcium content (Fig. 1) and alkaline phosphatase Rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and 3 h later the animals were orally administered b-cryptoxanthin (5 or 10 mg/100 g) once daily for 7 or 14 d. The animals were killed 24 h after the last administration. Each value is the meanϮS.E.M. for six rats. * pϽ0.01, compared with the control (none) value. # pϽ0.01, compared with the control value from STZ treatment. The procedure of administration is described in the legend to Table 1 . Each value is the meanϮS.E.M. for six rats. * pϽ0.01, compared with the control (none) value. # pϽ0.01, compared with the control value from STZ treatment. activity (Fig. 2) in the femoral-diaphyseal and -metaphyseal tissues were significantly decreased 7 or 14 d after the administration of STZ (6.0 mg/100 g), respectively. These decreases were significantly prevented by the administration of b-cryptoxanthin for 7 or 14 d. DNA content in the femoral-diaphyseal and -metaphyseal tissues was significantly decreased 7 or 14 d after the administration of STZ (6.0 mg/100 g) (Fig.  3) . The decrease was not caused by the administration of b- The procedure of administration is described in the legend to Table 1 . Rats were killed 7 or 14 d after STZ administration. Each value is the meanϮS.E.M. for six rats. * pϽ0.01, compared with the control (none) value. # pϽ0.01, compared with the control value from STZ treatment. White bars, control; black bars, STZ; hatched bars, STZϩb-cryptoxanthin (5 mg/100 g); double hatched bars, STZϩb-cryptoxanthin (10 mg/100 g). The procedure of administrating is described in the legend to Table 1 . Rats were killed 7 or 14 d after STZ administration. Each value is the meanϮS.E.M. for six rats. * pϽ0.01, compared with the control (none) value. # pϽ0.01, compared with the control value from STZ treatment. White bars, control; black bars, STZ; hatched bars, STZϩb-cryptoxanthin (5 mg/100 g); double hatched bars, STZϩb-cryptoxanthin (10 mg/100 g). The procedure of administration is described in the legend to Table 1 . Rats were killed 7 or 14 d after STZ administration. Each value is the meanϮS.E.M. for six rats. * pϽ0.01, compared with the control (none) value. # pϽ0.01, compared with the control value from STZ treatment. White bars, control; black bars, STZ; hatched bars, STZϩb-cryptoxanthin (5 mg/100 g); double hatched bars, STZϩb-cryptoxanthin (10 mg/100 g). cryptoxanthin (5 or 10 mg/100 g) for 7 or 14 d. Metaphyseal DNA content was significantly decreased 14 d after STZ administration. This decrease was significantly prevented by the administration of b-cryptoxanthin (5 or 10 mg/100 g) for 14 d. The administration of b-cryptoxanthin (5 or 10 mg/ 100 g) to normal rats for 14 d caused a significant increase in calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues (data not shown).
DISCUSSION
The administration of STZ to rats caused a significant increase in serum glucose and triglyceride levels, indicating a diabetic state. STZ administration also induced a significant increase in serum calcium and a significant decrease in serum inorganic phosphorus levels, suggesting a disorder of bone metabolism. Moreover, the augmentation of body weight was significantly retarded in the STZ-diabetic state. These alterations were significantly prevented by oral administration of b-cryptoxanthin to STZ-diabetic rats. The present findings demonstrate that the intake of b-cryptoxanthin has preventive effects against the diabetic state.
Bone loss may be induced in the diabetic state. [23] [24] [25] Calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal (cortical bone) and -metaphyseal (trabecular bone) tissues was significantly decreased in STZ-diabetic rats. Alkaline phosphatase is an enzyme marker of osteoblasts and the enzyme participates in bone mineralization. 26 ) DNA content in bone tissues is an index of the number of bone cells. 27) Presumably, STZ administration induces bone loss by inhibiting osteoblastic bone formation and stimulating osteoclastic bone resorption.
Oral administration of b-cryptoxanthin was found to have a preventive effect on the decrease in calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues of STZ-diabetic rats. bCryptoxanthin has been shown to have a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption in vitro. [11] [12] [13] [14] The effect of bcryptoxanthin in preventing bone loss in STZ-diabetic rats may result from b-cryptoxanthin stimulating osteoblastic bone formation and inhibiting osteoclastic bone resorption. As a result, oral administration of b-cryptoxanthin may restore the hypercalcemia and hypophosphatemia induced in the diabetic state.
Oral administration of b-cryptoxanthin was found to have a significant preventive effect on the increase in glucose and triglyceride levels in the serum of STZ-administered rats. The mechanism by which b-cryptoxanthin administration has a partial preventive effect on the serum components in STZdiabetic rats is unknown. It is speculated that b-cryptoxanthin administration stimulates the tissue transport of serum glucose and triglycerids. This remains to be elucidated.
It has been reported that the serum concentrations of bcryptoxanthin increases due to the consumption of vegetable juice in women in the range of 1.34ϫ10 Ϫ7 to 5.3ϫ10 Ϫ7 M.
28)
The anabolic effect of b-cryptoxanthin on bone formation and bone resorption was observed to 10 Ϫ8 and 10 Ϫ7 M in vitro. 11) Presumably, the supplemental intake of b-cryptoxanthin has a preventive effect on bone loss induced in the diabetic state in vivo.
In conclusion, it has been demonstrated that the oral administration of b-cryptoxanthin can prevent bone loss in STZ-diabetic rats and that the administration has a partial preventive effect on the increase in serum glucose and triglyceride levels with diabetes in vivo.
